Psychiatric Symptoms

Chapter

Abstract

Psychiatric symptoms often occur in patients with systemic lupus erythematosus (SLE). According to the American College of Rheumatology (ACR) research committee criteria for neuropsychiatric SLE (NPSLE) in 1999, the psychiatric symptoms include acute confusional state (delirium), anxiety disorder, cognitive dysfunction, mood disorder, and psychosis. Because no diagnostic gold standard exists for primary NPSLE, it is often difficult to distinguish primary cause-and-effect association of the symptom as a direct attribute of active disease from a secondary, indirect effect resulting from complications of the disease or its therapy (e.g. corticosteroids), or an effect unrelated to SLE. On one hand, conditions such as psychosis, anxiety disorder and mood disorder can also present as psychological reaction to the disease and the related stress. On the other hand, possible mechanisms include microvasculopathy and thrombosis, or autoantibodies and inflammatory mediators. Therefore, in lupus patients presenting with psychiatric symptoms, a careful diagnostic work-up including, but not limited to, psychiatric/neuropsychological assessment, immunological/medical investigation, as well as neuroimaging is crucial in delivering adequate medical care and treatment.

Keywords

Lupus Psychosis Depression Anxiety Acute confusional state Cognitive dysfunction 

References

  1. 1.
    Ainiala H, et al. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology. 2001;57:496–500.CrossRefPubMedGoogle Scholar
  2. 2.
    Brey RL, et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology. 2002;58:1214–20.CrossRefPubMedGoogle Scholar
  3. 3.
    Hanly JG, et al. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J Rheumatol. 2004;31:2156–62.PubMedGoogle Scholar
  4. 4.
    Unterman A, et al. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum. 2011;41:1–11.CrossRefPubMedGoogle Scholar
  5. 5.
    ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology Nomenclature and Case Definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599–608.CrossRefGoogle Scholar
  6. 6.
    Postal M, et al. Neuropsychiatric manifestations in systemic lupus erythematosus: epidemiology, pathophysiology and management. CNS Drugs. 2011;25:721–36.CrossRefPubMedGoogle Scholar
  7. 7.
    Bertsias GK, Boumpas DT. Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nat Rev Rheumatol. 2010;6:358–67.CrossRefPubMedGoogle Scholar
  8. 8.
    Hanly JG. Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol. 2014;10:338–47.CrossRefPubMedGoogle Scholar
  9. 9.
    Hanly JG, et al. Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study. Arthritis Rheum. 2008;59:721–9.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Hanly JG, et al. Prospective study of neuropsychiatric events in systemic lupus erythematosus. J Rheumatol. 2009;36:1449–59.CrossRefPubMedGoogle Scholar
  11. 11.
    Hanly JG, et al. Systemic Lupus International Collaborating Clinics (SLICC): prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2010;69:529–35.CrossRefPubMedGoogle Scholar
  12. 12.
    American Psychiatric Association, editor. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.Google Scholar
  13. 13.
    Pego-Reigosa JM, Isenberg DA. Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease. Rheumatology. 2008;47:1498–502.CrossRefPubMedGoogle Scholar
  14. 14.
    Appenzeller S, et al. Acute psychosis in systemic lupus erythematosus. Rheumatol Int. 2008;28:237–43.CrossRefPubMedGoogle Scholar
  15. 15.
    Paholpak P, et al. Characteristics, treatments and outcome of psychosis in Thai SLE patients. J Psychosom Res. 2012;73:448–51.CrossRefPubMedGoogle Scholar
  16. 16.
    Isshi K, Hirohata S. Differential roles of the anti-ribosomal P antibody and antineuronal antibody in the pathogenesis of central nervous system involvement in systemic lupus erythematosus. Arthritis Rheum. 1998;41:1819–27.CrossRefPubMedGoogle Scholar
  17. 17.
    Toubi E, Shoenfeld Y. Clinical and biological aspects of anti-P-ribosomal protein autoantibodies. Autoimmun Rev. 2007;6:119–25.CrossRefPubMedGoogle Scholar
  18. 18.
    Karassa FB, et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum. 2006;54:312–24.CrossRefPubMedGoogle Scholar
  19. 19.
    Hirohata S, et al. Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study. Clin Rheumatol. 2009;28:1319–23.CrossRefPubMedGoogle Scholar
  20. 20.
    Zhang L, et al. Prevalence of depression and anxiety in systemic lupus erythematosus: a systematic review and meta-analysis. BMC Psychiatry. 2017;17:70.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Palagini L, et al. Depression and systemic lupus erythematosus: a systematic review. Lupus. 2013;22:409–16.CrossRefPubMedGoogle Scholar
  22. 22.
    Bachen LA, et al. Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus. Arthritis Rheum. 2009;61:822–9.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Nery FG, et al. Prevalence of depressive and anxiety disorders in systemic lupus erythematosus and their association with antiribosomal P antibodies. Prog Neuro-Psychopharmacol Biol Psychiatry. 2008;32:695–700.CrossRefGoogle Scholar
  24. 24.
    Eber T, et al. Anti-ribosomal P-protein and its role in psychiatric manifestations of systemic lupus erythematosus: myth or reality? Lupus. 2005;14:571–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Giovacchini G, et al. Cerebral blood flow in depressed patients with systemic lupus erythematosus. J Rheumatol. 2010;37:1844–51.CrossRefPubMedGoogle Scholar
  26. 26.
    Saito T, et al. Regional cerebral glucose metabolism in systemic lupus erythematosus patients with major depressive disorder. J Neurol Sci. 2017;379:127–30.CrossRefPubMedGoogle Scholar
  27. 27.
    Katsumata Y, et al. Diagnostic reliability of cerebral spinal fluid tests for acute confusional state (delirium) in patients with systemic lupus erythematosus: interleukin 6 (IL-6), IL-8, interferon-alpha, IgG index, and Q-albumin. J Rheumatol. 2007;34:2010–7.PubMedGoogle Scholar
  28. 28.
    Panopalis P, et al. Impact of memory impairment on employment status in persons with systemic lupus erythematosus. Arthritis Rheum. 2007;57:1453–60.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Ad Hoc Committee on Lupus Response Criteria, Cognition Sub-committee, Mikdashi JA, et al. Proposed response criteria for neurocognitive impairment in systemic lupus erythematosus clinical trials. Lupus. 2007;16:418–25.CrossRefGoogle Scholar
  30. 30.
    Kozora E, et al. Cognitive dysfunction in systemic lupus erythematosus: past, present, and future. Arthritis Rheum. 2008;58:3286–98.CrossRefPubMedGoogle Scholar
  31. 31.
    Brown ES. Effects of glucocorticoids on mood, memory, and the hippocampus. Treatment and preventive therapy. Ann NY Acad Sci. 2009;1179:41–55.CrossRefPubMedGoogle Scholar
  32. 32.
    Nishimura K, et al. Neurocognitive impairment in corticosteroid-naive patients with active systemic lupus erythematosus: a prospective study. J Rheumatol. 2015;42:441–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Filley CM. White matter: organization and functional relevance. Neuropsychol Rev. 2010;20:158–73.CrossRefPubMedGoogle Scholar
  34. 34.
    Appenzeller S, et al. Neurometabolic changes in normal white matter may predict appearance of hyperintense lesions in systemic lupus erythematosus. Lupus. 2007;16:963–71.CrossRefPubMedGoogle Scholar
  35. 35.
    Filley CM, et al. White matter microstructure and cognition in non-neuropsychiatric systemic lupus erythematosus. Cogn Behav Neurol. 2009;22:38–44.CrossRefPubMedGoogle Scholar
  36. 36.
    Ramage AE, et al. Neuroimaging evidence of white matter inflammation in newly diagnosed systemic lupus erythematosus. Arthritis Rheum. 2011;63:3048–57.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Tomietto P, et al. General and specific factors associated with severity of cognitive impairment in systemic lupus erythematosus. Arthritis Rheum. 2007;57:1461–72.CrossRefPubMedGoogle Scholar
  38. 38.
    Sanna G, et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol. 2003;30:985–92.PubMedGoogle Scholar
  39. 39.
    Grover S, et al. Catatonia in systemic lupus erythematosus: a case report and review of literature. Lupus. 2013;22:634–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Bica BE, et al. Electroconvulsive therapy as a treatment for refractory neuropsychiatric lupus with catatonia: three case studies and literature review. Lupus. 2015;24:1327–31.CrossRefPubMedGoogle Scholar
  41. 41.
    Wang HY, Huang TL. Benzodiazepines in catatonia associated with systemic lupus erythematosus. Psychiatry Clin Neurosci. 2006;60:768–70.CrossRefPubMedGoogle Scholar
  42. 42.
    Ishikura R, et al. Factors associated with anxiety, depression and suicide ideation in female outpatients with SLE in Japan. Clin Rheumatol. 2001;20:394–400.CrossRefPubMedGoogle Scholar
  43. 43.
    Mok CC, et al. Suicidal ideation in patients with systemic lupus erythematosus: incidence and risk factors. Rheumatology. 2014;53:714–21.CrossRefPubMedGoogle Scholar
  44. 44.
    Hajduk A, et al. Prevalence and correlates of suicidal thoughts in patients with neuropsychiatric lupus. Lupus. 2016;25:185–92.CrossRefPubMedGoogle Scholar
  45. 45.
    Tang KT, et al. Suicidal drug overdose in patients with systemic lupus erythematosus, a nationwide population-based case-control study. Lupus. 2016;25:199–203.CrossRefPubMedGoogle Scholar
  46. 46.
    Bhangle SD, et al. Corticosteroid-induced neuropsychiatric disorders: review and contrast with neuropsychiatric lupus. Rheumatol Int. 2013;33:1923–32.CrossRefPubMedGoogle Scholar
  47. 47.
    Chau SY, Mok CC. Factors predictive of corticosteroid psychosis in patients with systemic lupus erythematosus. Neurology. 2003;61:104–7.CrossRefPubMedGoogle Scholar
  48. 48.
    Nishimura K, et al. Blood-brain barrier damage as a risk factor for corticosteroid-induced psychiatric disorders in systemic lupus erythematosus. Psychoneuroendocrinology. 2008;33:395–403.CrossRefPubMedGoogle Scholar
  49. 49.
    Nishimura K, et al. New-onset psychiatric disorders after corticosteroid therapy in systemic lupus erythematosus: an observational case-series study. J Neurol. 2014;261:2150–8.CrossRefPubMedGoogle Scholar
  50. 50.
    Nishimura K, et al. Risperidone in the treatment of corticosteroid-induced mood disorders, manic/mixed episodes, in systemic lupus erythematosus: a case series. Psychosomatics. 2012;53:289–93.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of PsychiatryTokyo Women’s Medical University School of MedicineTokyoJapan

Personalised recommendations